Gilead's primary areas of focus include HIV/AIDS, liver disease and serious cardiovascular/metabolic and respiratory conditions.
Our portfolio of 13 marketed products includes a number of category firsts and market leaders, including Atripla® (efavirenz 600 mg/emtricitabine 200 mg/ tenofovir disoproxil fumarate 300 mg) - the first single-tablet regimen for HIV infection. Viread® (tenofovir disoproxil fumarate), the company's first agent approved for HIV infection, was also approved in 2008 for the treatment of chronic hepatitis B.
More than 20 Years of Growth
Gilead was founded in 1987 in Foster City, California. In just over 20 years, Gilead has become a leading biopharmaceutical company with a rapidly expanding product portfolio, growing pipeline of investigational drugs and approximately 4,000 employees.
In 2009, Gilead's annual revenues surpassed $7 billion. BusinessWeek ranked Gilead #1 in its 2009 listing of the 50 best-performing companies, up from #2 in 2008.